| 前收市價 | 1,356.95 |
| 開市 | 1,402.00 |
| 買盤 | 1,404.05 x 0 |
| 賣出價 | 1,408.55 x 0 |
| 今日波幅 | 1,386.65 - 1,427.70 |
| 52 週波幅 | 913.20 - 1,519.00 |
| 成交量 | |
| 平均成交量 | 41,917 |
| 市值 | 1.135T |
| Beta 值 (5 年，每月) | 0.37 |
| 市盈率 (最近 12 個月) | 27.56 |
| 每股盈利 (最近 12 個月) | 51.02 |
| 業績公佈日 | 2024年7月24日 - 2024年7月29日 |
| 遠期股息及收益率 | 13.00 (0.96%) |
| 除息日 | 2024年8月01日 |
| 1 年預測目標價 | 無 |
- Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
- Reuters
India pharma companies develop versions of Wegovy to get in on weight-loss windfall
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions of Novo Nordisk's wildly in demand Wegovy. With some analysts predicting a weight-loss market reaching $100 billion a year or more by the end of the decade, executives at Sun Pharma, Cipla, Dr Reddy's and Lupin -- some of the world's largest generic drugmakers -- all said they have started work on Wegovy versions. Novo Nordisk has been unable to produce enough Wegovy to meet demand in more than half a dozen countries where it has already launched, amid record global obesity rates and people looking for easier alternatives to diet and exercise.
